SCHEMBL6651907

SCHEMBL6651907

CC(C)(C)[SiH2]OC(c1ccccc1)(c1ccccc1)C1CN(Cc2ccccc2)CCC1(O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2D6 P10635 1/20 0.38
KCNH2 Q12809 1/20 0.38
OPRL1 P41146 1/20 0.37
CCR3 P51677 1/20 0.37
POLB P06746 1/20 0.37
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
KDM4E B2RXH2 1/20 0.34
NPY1R P25929 1/20 0.34
HTT P42858 1/20 0.34
NPY2R P49146 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042422 0.92 ALDH1A1 (0.42) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL6042627 0.72 ALDH1A1 (0.43) ALDH1A1KMT2AMEN1
SCHEMBL6651905 0.70 ALDH1A1 (0.43) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL6042725 0.70 TACR1 (0.49) KMT2AMEN1
SCHEMBL6651904 0.69 ALDH1A1 (0.52) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL3890625 0.66 OPRL1 (0.82) KMT2AOPRL1CCR3POLBDRD2
SCHEMBL6042461 0.65 SIGMAR1 (0.44) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL4076057 0.65 ALDH1A1 (0.57) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL16799739 0.65 ALDH1A1 (0.57) ALDH1A1KMT2ATSHRMEN1LMNA
SCHEMBL11558827 0.65 ALDH1A1 (0.67) ALDH1A1KMT2ATSHRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 EP disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP ALDH1A1 2007/4885KMT2A 1940/4885TSHR 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.